1、Erlotinib HydrochlorideCat. No.: HY-12008CAS No.: 183319-69-9Molecular Formula: CHClNOMolecular Weight: 429.9Target: EGFR; AutophagyPathway: JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; AutophagyStorage: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 monthSolvent Need ultrasonic and
2、 warming)ConcentrationSolvent Mass 1 mg 5 mg 10 mg1 mM 2.3261 mL 11.6306 mL 23.2612 mL5 mM 0.4652 mL 2.3261 mL 4.6522 mLPreparing Stock Solutions10 mM 0.2326 mL 1.1631 mL 2.3261 mLPlease refer to the solubility information to select the appropriate solvent.BIOLOGICAL ACTIVITYDescription Erlotinib hy
3、drochloride inhibits purified EGFR kinase with an IC50 of 2 nM.IC 36(19):2643-2654. J Invest Dermatol. 2018 Aug 3. pii: S0022-202X(18)32461-8. Mol Oncol. 2018 Mar;12(3):305-321.www.MedChemE2See more customer validations on www.MedChemEREFERENCES1. Moyer JD, et al. Induction of apoptosis and cell cyc
4、le arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res. 1997 Nov 1;57(21):4838-48.2. Ali S, et al. Apoptosis-inducing effect of erlotinib is potentiated by 3,3-diindolylmethane in vitro and in vivo using an orthotopic model of pancreatic cancer. Mol Can
5、cer Ther, 2008, 7(6), 1708-1719.3. Marchetti S, et al. Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-typ4. Adachi
6、K, et al. Effects of erlotinib on lung injury induced by intratracheal administration of bleomycin (BLM) in rats. J Toxicol Sci. 2010 Aug;35(4):503-14.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: techMedChemEAddress: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA Oncotarget. 2017 Dec 2;8(68):112313-112329. Anal Chim Acta. 2018 Nov 22;1032:138-146.www.MedChemE3
